Reuter U, et al. Long-term efficacy and safety of erenumab: Results from 64 weeks of the LIBERTY study. IHC-OR-006. IHC 2019 5-8 sept. Dublin, Ierland.
Briljante technologische doorbraak zoekt toepassing
mei 2022 | Neuro-musculair
jan 2024 | Neuro-vasculair
dec 2023 | Bewegingsstoornissen